- Penumbra Inc PEN posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million.
- Revenue from sales of vascular products grew 30.4% (31.1%) to $113.6 million.
- Revenue from sales of neuro products grew 13.3% (14.1%) to $90.4 million.
- The gross margin was 61.5%, impacted by higher labor and logistics costs due to inflation. This compares to the gross profit margin of 56.5% in Q4 FY20.
- The Company reported a Q4 operating loss of $(40.9) million wider than $(1.7) million posted a year ago.
- The Company reported an EPS loss of $(0.66), a turnaround from a profit of $0.10.
- “In the fourth quarter, we achieved record revenue in both our neuro and vascular businesses. Also, we started making progress toward our goal of building a safe and secure healthcare platform using immersive computing to help a significant number of patients,” CEO Adam Elsesser said during an earnings call.
- Guidance: Penumbra expects FY22 sales of $860 million - $875 million, representing 15% - 18% growth over 2021, compared to the consensus of $862.41 million.
- Price Action: PEN shares are down 2.12% at $212 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in